US President Donald Trump on Friday blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans, but healthcare stocks rose as experts said the administration avoided taking aggressive and direct measures to cut drug prices.
Trump said his administration would take aim at the “middlemen” in the drug industry who have become “very, very rich,” an apparent reference to health insurers and pharmacy benefit managers. He also said the pharmaceutical industry is making an “absolute fortune” at the expense of US taxpayers.
“Everyone involved in the broken system — the drugmakers, insurance companies, distributors, pharmacy benefit managers and many others — contribute to the problem,” Trump said.
Photo: AP
Shares of the major US companies in each of those sectors rose after the speech, with the S&P 500 healthcare sector, a broad gauge of large healthcare stocks, up 1.4 percent.
Trump also placed blame on foreign governments, which negotiate lower drug prices than in the US, saying they “extort” unreasonably low prices from US drugmakers.
Trump was speaking as his health deputies released a series of proposals to address high drug costs.
The US Department of Health and Human Services released what it called a blueprint titled “American Patients First” with details of its plan.
The administration’s immediate actions would include allowing commercial plans that administer Medicare Part D prescription drug benefits for seniors more power to negotiate prices with drugmakers, it said.
The US Food and Drug Administration would evaluate requiring drugmakers to include the list prices they set on medicines in their advertising.
Drugmakers argue that list prices do not reflect actual cost with discounts and rebates.
Some of the administration’s longer-term priorities include restricting use of rebates, creating incentives for drugmakers to lower list prices and investigating tools to address foreign government practices that it said could be harming innovation and driving up US prices.
Healthcare experts said Trump’s plan sounded like rhetoric rather than substantive change for an industry where prices rise substantially more than inflation each year.
“There’s not a big proposal here that is going to make a huge difference. There are a bunch of smaller technical changes,” Boston College associate professor of economics Sam Richardson said.
Regarding forcing other countries to pay more for drugs, Richardson said: “We don’t really have the policy levers to get that to happen.”
Secretary of Health and Human Services Alex Azar said during a White House briefing that many of the actions the government was considering would not require the US Congress, but could take place through executive action within months. He said it would take years to restructure the US drug system.
Healthcare stocks were volatile during Trump’s speech, with shares of companies involved in the pharmaceutical supply chain, such as Express Scripts Holding Co and CVS Health Corp, hitting session lows. However, those stocks quickly reversed course, with Express Scripts shares up 2.4 percent and CVS up 3 percent.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Chizuko Kimura has become the first female sushi chef in the world to win a Michelin star, fulfilling a promise she made to her dying husband to continue his legacy. The 54-year-old Japanese chef regained the Michelin star her late husband, Shunei Kimura, won three years ago for their Sushi Shunei restaurant in Paris. For Shunei Kimura, the star was a dream come true. However, the joy was short-lived. He died from cancer just three months later in June 2022. He was 65. The following year, the restaurant in the heart of Montmartre lost its star rating. Chizuko Kimura insisted that the new star is still down
While China’s leaders use their economic and political might to fight US President Donald Trump’s trade war “to the end,” its army of social media soldiers are embarking on a more humorous campaign online. Trump’s tariff blitz has seen Washington and Beijing impose eye-watering duties on imports from the other, fanning a standoff between the economic superpowers that has sparked global recession fears and sent markets into a tailspin. Trump says his policy is a response to years of being “ripped off” by other countries and aims to bring manufacturing to the US, forcing companies to employ US workers. However, China’s online warriors
RSS